Stefano Bertozzi

Global Initiative for Psychedelic Science Economics (GIPSE), University of California, Berkeley, Berkeley, CA, United States.

2 papers in the library · 91 citations · publishing 2022-2023

Papers

The economics of psychedelic-assisted therapies: A research agenda

Frontiers in Psychiatry December 5, 2022 Elliot Marseille, Stefano Bertozzi, James G Kahn 51 citations

Psychiatry is seeing renewed interest in using psychedelic drugs to treat mental health disorders like depression, PTSD, and addictions, with clinical evidence showing substantial potential. New therapies could become available by 2024 for patients who do not respond to traditional treatments. However, research on economic factors such as costs, cost-effectiveness, pricing, and the economic effects of widespread implementation has lagged. These issues are critical for making psychedelic therapies widely accessible. The authors describe six types of economic analyses relevant to decisions and planning, including the needs of healthcare payers, and outline desirable features of such research, including scientific rigor, long-term horizons, equity, and a global perspective.

DOI: 10.3389/fpsyt.2022.1025726 MDMA Psilocybin Cost-effectiveness Health economics +6

Group psychedelic therapy: empirical estimates of cost-savings and improved access

Frontiers in Psychiatry December 6, 2023 Elliot Marseille, Manish Agrawal, Paul Thambi et al. 40 citations

Group psychedelic-assisted therapy, compared with individual therapy, reduces clinician costs by 50.9% for MDMA treatment of PTSD and 34.7% for psilocybin treatment of major depressive disorder, saving $3,467 and $981 per patient respectively. Using 2023 data from two trial sites and published prevalence estimates, treating all eligible U.S. adults with PTSD or MDD over ten years with group therapy would require 6,711 fewer full-time clinicians for MDMA-PTSD and 1,159 fewer for psilocybin-MDD, saving up to $10.3 billion and $2.0 billion. Adopting group protocols could lower costs, ease clinician shortages, and expand patient access.

DOI: 10.3389/fpsyt.2023.1293243 MDMA Psilocybin Major depressive disorder Medicine +3